V
Varsha Gandhi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 339
Citations - 15816
Varsha Gandhi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 62, co-authored 318 publications receiving 14230 citations. Previous affiliations of Varsha Gandhi include University of Texas Health Science Center at Houston & University of Texas System.
Papers
More filters
Journal ArticleDOI
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai T. Tran,Robert J. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy L. Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun Ki Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach +33 more
TL;DR: A robust EMT signature is developed that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance associated with the mesenchyal phenotype.
Journal Article
Gemcitabine : metabolism, mechanisms of action, and self-potentiation
TL;DR: The unique actions that gemcitabine metabolites exert on cellular regulatory processes serve to enhance the overall inhibitory activities on cell growth and is evidenced in very few other anticancer drugs.
Journal ArticleDOI
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader,Shih Shih Chen,Joseph J. Buggy,Kumudha Balakrishnan,Varsha Gandhi,William G. Wierda,Michael J. Keating,Susan O'Brien,Nicholas Chiorazzi,Jan A. Burger +9 more
TL;DR: It is demonstrated that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent.
Journal ArticleDOI
Ibrutinib and venetoclax for first-line treatment of CLL
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yilmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias J. Jabbour,Koji Sasaki,Rashmi Kanagal-Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +31 more
TL;DR: Combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL and the proportions of patients who had complete remission or complete remission with incomplete count recovery and remission with undetectable minimal residual disease increased over time.
Journal ArticleDOI
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Antonina V. Kurtova,Kumudha Balakrishnan,Rong Chen,Wei Ding,Susanne Schnabl,Maite P. Quiroga,Mariela Sivina,William G. Wierda,Zeev Estrov,Michael J. Keating,Medhat Shehata,Ulrich Jäger,Varsha Gandhi,Neil E. Kay,William Plunkett,Jan A. Burger +15 more
TL;DR: Common denominators for CLL cocultures with MSCs are defined to provide a reliable, validated tool for future investigations into the mechanism of MSC-CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures.